Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 10 Mar 2021 – 20 Aug 2026, limited by ITI Mid Cap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | ITI Mid Cap Fund | Nifty Midcap 150 |
|---|---|---|
| 10 Mar 2021 | ₹100.00 | ₹100.00 |
| 23 Aug 2021 | ₹112.44 | ₹111.01 |
| 05 Feb 2022 | ₹113.76 | ₹124.98 |
| 20 Jul 2022 | ₹110.10 | ₹118.12 |
| 02 Jan 2023 | ₹121.02 | ₹130.55 |
| 17 Jun 2023 | ₹131.92 | ₹143.88 |
| 30 Nov 2023 | ₹160.11 | ₹174.10 |
| 13 May 2024 | ₹201.33 | ₹201.94 |
| 26 Oct 2024 | ₹223.44 | ₹224.27 |
| 10 Apr 2025 | ₹197.65 | ₹199.28 |
| 23 Sep 2025 | ₹232.27 | ₹236.81 |
| 07 Mar 2026 | ₹234.00 | ₹231.01 |
| 20 Aug 2026 | ₹262.90 | ₹255.08 |
| Metric | ITI · Direct NAV ₹26.28 Very High risk ★★★★☆ | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| +13.76% | +9.87% | |
| +23.34% | +19.74% | |
| +18.38% | +17.84% | |
| — | +17.01% | |
| +19.42% | +19.29% | |
| +20.26% | — | |
| +25.51% | +20.53% | |
| +18.25% | +19.07% | |
| — | +18.49% | |
| Risk | ||
| 18.04% | 16.20% | |
| 0.93 | 0.83 | |
| 1.24 | 1.14 | |
| -22.66% | -32.95% | |
| Nifty Midcap 150 | — | |
| +4.34% | +2.33% | |
| 1.02 | 0.94 | |
| 107.1% | 98.4% | |
| 87.6% | 87.8% | |
| 0.94% | 0.97% | |
| ₹1,370Cr | ₹7,594Cr | |
| 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 85% | 40% | |
| Rohan Korde · 4.3y | — | |
| 10 Mar 2021 | — | |
| 88 | — | |
| 18.9% | — | |
| 2.5% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.